On this page
What it is
A synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) developed from work on pineal extracts at the St Petersburg Institute of Bioregulation and Gerontology. Cardiogen, Cartalax, Pinealon, Testagen and Vesugen come from the same series and share its research lineage.
How it is proposed to work
The series hypothesis is that very short peptides reach the nucleus and modulate gene expression in a sequence-specific way, with each peptide matched to a tissue — here the pineal gland. A separate and much stronger claim, that it raises telomerase activity, carries most of the public discussion and is the least supported part of the chain.
Approved medical uses
None. Epitalon has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Controlled human trial2003n = 266
Six-to-eight-year controlled follow-up of Thymalin and Epithalamin — not the AEDG tetrapeptide
Finding. The compounds assessed here are Epithalamin, a peptide preparation of the pineal gland, and the thymic preparation Thymalin — not the synthetic Ala-Glu-Asp-Gly tetrapeptide this dossier covers. In 266 elderly and older persons clinically assessed over six to eight years, with the bioregulators applied during the first two to three years of observation, the authors report a lower mortality rate than control in each treated group: 1.6-1.8-fold lower with Epithalamin, 2.0-2.1-fold lower with Thymalin, and 2.5-fold lower with the two combined. A separately described group treated with both annually for six years is reported at 4.1-fold lower than control; the abstract does not say whether that group sits within the 266. Acute respiratory disease incidence fell 2.0-2.4-fold against control, and the authors also report reduced incidence of the clinical manifestations of ischaemic heart disease, hypertension, deforming osteoarthrosis and osteoporosis, without figures.
Limitation. Not independently replicated as far as we could establish, which is the central reason for the grade. What was tested is Epithalamin, the pineal peptide preparation, alongside the thymic preparation Thymalin; the report does not mention the synthetic Ala-Glu-Asp-Gly tetrapeptide, so it supplies no human evidence for the compound this dossier covers. The abstract describes a clinical assessment against a control group but does not state how participants were allocated or whether anyone was blinded, and it prints only the single total of 266 without saying how many sat in each treated group or in the control. Outcomes are given as fold-differences with no confidence intervals or p-values in the abstract, and the report comes from the two institutes that ran and are reporting on their own peptide programme. All of the above is read from the abstract; we have not read the full report. The same work appears in Russian a year earlier in Adv Gerontol (PMID 12577695) with the same total, the same follow-up window, the same dosing window and the same fold-differences, so the two are one dataset rather than a replication.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionInsufficient
If a compound genuinely increased telomerase activity, the oncological implications would need serious study. That study has not been done.
Known interactions and contraindication considerations
- Not characterised.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
Russian Federation Ministry of Health / Roszdravnadzor | Listed as of 20 Sept 2026 | Marketed in Russia, generally in a supplement or parapharmaceutical category rather than as a registered medicine. Certificate details in circulation could not be verified against the state register and are not reproduced here. |
United States FDA | Not approved as of 24 Jul 2026 | Not approved. Has appeared in compounding-category discussion, which is a stage in an evaluation and not an approval. |
European Union EMA | Unapproved / investigational as of 1 Jun 2026 | No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | Not approved for human use. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Anti-ageing courses and sleep
What is run
Short daily courses once or twice a year, sometimes reported for sleep quality alongside the ageing rationale.
Their mechanistic reasoning
That it raises telomerase activity and regulates pineal melatonin production, based on older cohort reports suggesting mortality differences.
Reported in the community’s own terms. Not our position.
Stacked with
- Consumer epigenetic age testing—Used as the outcome measure, which is the weakest part of the practice.
Regimen shape
- Dose
- figure withheld
- Scale
- Milligram-scale
- Route
- Subcutaneous injection
- Frequency
- Daily during a course
- Timing
- Evening in sleep-oriented use
- Duration
- Short courses, once or twice a year
Our read
The telomerase claim carries the whole argument and is the least supported part of it. The original work comes from a single research tradition with reporting that would not meet current standards, and independent replication is essentially absent. The pineal and sleep rationale is at least mechanistically coherent, which is more than can be said for the ageing claim — but it is equally untested.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
A committed minority believe strongly, but the wider longevity community has grown more sceptical as the weakness of the original evidence has become better known. Sleep reports are more consistent than ageing claims.
Commonly reported as helping
- Improved sleep quality during courses
- Improved epigenetic age test results, cited frequently
- Vague reports of wellbeing
Also reported, when it goes wrong
- No noticeable effect for many
- Epigenetic results moving in the wrong direction for some
- Growing scepticism about the underlying research
Why these reports can mislead
Epigenetic clock results are the headline outcome and have measurement variability large enough that a change between two tests is frequently noise. Running the same test twice in one week would demonstrate this, and almost nobody does.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Run the same epigenetic test twice in one week before treating any change as a result.
- Discuss with a clinician if you have personal or family cancer history, given the unstudied telomerase claim.
Active clinical trials
No registered trials currently tracked for Epitalon.
What remains unknown
The questions that would change our assessment if they were answered.
- Can any of the original findings be independently replicated under modern methodology?
- Is there any measurable telomerase effect in humans at all?
- Does a peptide this short reach the nucleus intact in a human?
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Reframed for consistency with the five Khavinson siblings added later. The grade is unchanged — it was and is about absent independent replication — but the wording previously leaned on Western reporting conventions as the yardstick, which conflated a discoverability limit with a quality verdict. Russian marketing status added; certificate details withheld as unverifiable.
Downgraded from preliminary to insufficient after independent-replication search returned nothing.
Spotted something wrong? Tell us — we publish corrections.